SG3 Management’s Guardant Health GH Stock Holding History

SG3 Management’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-7,000	Closed	-$320K	–	262
2022 Q3	$377K	Buy	+7,000	New	+$359K	0.05%	163
2022 Q1	–	Sell	-8,000	Closed	-$547K	–	1115
2021 Q4	$800K	Buy	+8,000	New	+$827K	0.02%	534

Other funds holding GH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

SG3 Management's GH Position: Q4 2022 in Review

SG3 Management sold out of Guardant Health (GH) in Q4 2022, closing a stake of 7,000 shares — an estimated $320K sold.

SG3 Management first reported a position in GH in Q4 2021 and held it in 2 quarters. The position peaked at $800K in Q4 2021. 292 funds tracked by Wall St. Rank hold GH as of Q4 2022.

SG3 Management reported no remaining Guardant Health position as of Q4 2022 after selling out during the quarter.
SG3 Management sold 7,000 Guardant Health shares in Q4 2022, an estimated $320K.
SG3 Management first reported a position in Guardant Health in Q4 2021 and held it in 2 quarters.
SG3 Management's Guardant Health position peaked at $800K in Q4 2021.
292 funds tracked by Wall St. Rank held Guardant Health as of Q4 2022.

Based on SG3 Management's 13F filing for Q4 2022, filed 14 Feb 2023.